0000899243-19-006334.txt : 20190305
0000899243-19-006334.hdr.sgml : 20190305
20190305210638
ACCESSION NUMBER: 0000899243-19-006334
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190301
FILED AS OF DATE: 20190305
DATE AS OF CHANGE: 20190305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Knappertz Volker
CENTRAL INDEX KEY: 0001754122
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35892
FILM NUMBER: 19661031
MAIL ADDRESS:
STREET 1: SOVEREIGN HOUSE, VISION PARK, HISTON
CITY: CAMBRIDGE
STATE: X0
ZIP: CB249BZ
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GW PHARMACEUTICALS PLC
CENTRAL INDEX KEY: 0001351288
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: SOVEREIGN HOUSE
STREET 2: VISION PARK
CITY: HISTON, CAMBRIDGE CB24 9BZ
STATE: X0
ZIP: 00000
BUSINESS PHONE: 44 1223 266800
MAIL ADDRESS:
STREET 1: SOVEREIGN HOUSE
STREET 2: VISION PARK
CITY: HISTON, CAMBRIDGE CB24 9BZ
STATE: X0
ZIP: 00000
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-03-01
0
0001351288
GW PHARMACEUTICALS PLC
GWPH
0001754122
Knappertz Volker
SOVEREIGN HOUSE, VISION PARK, HISTON
CAMBRIDGE
X0
CB24 9BZ
UNITED KINGDOM
0
1
0
0
Chief Medical Officer
Ordinary Shares
2019-03-01
4
S
0
3732
14.46
D
8736
D
Stock Options
14.33
2019-03-01
4
A
0
48252
0.00
A
2022-03-01
2029-03-01
Ordinary Shares
48252
48252
D
Stock Options
0.0013
2019-03-01
4
A
0
91584
0.00
A
2022-03-01
2023-03-15
Ordinary Shares
91584
91584
D
Stock Options
0.0013
2019-03-01
4
A
0
6864
0.00
A
2020-03-01
Ordinary Shares
6864
6864
D
Stock Options
0.0013
2019-03-01
4
A
0
6864
0.00
A
2021-03-01
Ordinary Shares
6864
6864
D
Stock Options
0.0013
2019-03-01
4
A
0
6864
0.00
A
2022-03-01
Ordinary Shares
6864
6864
D
Stock Options
0.0013
2019-03-01
4
A
0
6864
0.00
A
2023-03-01
Ordinary Shares
6864
6864
D
Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer.
The price reported in Column 4 is price per ordinary share converted from price per ADS.
Granted pursuant to the Issuer's Long-Term Incentive Plan.
The reported options are options to purchase ADSs.
The exercise price reported is price per ordinary share converted from price per ADS ($172.01).
Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019.
These stock options will vest automatically on exercisable date.
/s/ Volker Knappertz
2019-03-05